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Introduction {#sec005}
============

Toxoplasmosis is a serious endemic disease caused by an intracellular parasite called *Toxoplasma gondii* (*T*. *gondii*). According to the seroepidemiological studies, this parasite infects about 15--85% of the total population of the world \[[@pntd.0008103.ref001]--[@pntd.0008103.ref003]\]. The only known definitive hosts for *T*. *gondii* are members of family Felidae, including domestic and wild cats. On the other hand, various warm-blooded mammals, including humans and rodents can be the intermediate host of this parasite \[[@pntd.0008103.ref004]\]. Human infections are acquired through several major ways: 1) consumption of undercooked meat especially pork and mutton and unpasteurized milk from infected animals, 2) direct or indirect contact with oocysts from the environment, 3) vertical transmission during pregnancy, 4) blood transfusions, and 5) organ transplants \[[@pntd.0008103.ref005]--[@pntd.0008103.ref008]\]. *T*. *gondii* infection is generally asymptomatic in immunologically healthy adults. However, it can cause a variety of life-threatening clinical complications in immunocompromised patients \[[@pntd.0008103.ref009]\]. This parasite is of utmost importance during pregnancy since it can cross the placental barrier to infect embryonic tissues \[[@pntd.0008103.ref010], [@pntd.0008103.ref011]\]. If this infection occurs during the first and second trimester of pregnancy, it may manifest in severe symptoms, such as low birth weight, hydrocephaly, intracranial calcifications, and retinochoroiditis that are recognizable at birth \[[@pntd.0008103.ref012]\]. On the other hand, infections in the third trimester of pregnancy do generally not show symptoms at birth; however, they may develop intracranial calcifications, hearing impairment, visual disorders, and developmental delay later in life \[[@pntd.0008103.ref013]\]. The global annual incidence rate of congenital toxoplasmosis (CT) is estimated to be 190,100 cases with an approximate incidence rate of 1.5 cases per 1000 live births \[[@pntd.0008103.ref014]\]. Effective factor in transplacental transmission and severity of CT depends on the time of maternal infection \[[@pntd.0008103.ref015]\]. There are two types of miscarriage: sporadic and recurrent \[[@pntd.0008103.ref016]\]. Spontaneous pregnancy loss is a clinical problem of pregnancy occurring in 15% of all clinically recognized pregnancies \[[@pntd.0008103.ref017]\]. The diagnosis of CT for the prevention of abortion is based on laboratory techniques, monitoring the immune response, direct detection of the parasite by animal or tissue inoculation, and molecular techniques \[[@pntd.0008103.ref018]\].

Some of the risk factors of abortion cited in different studies include ethnicity, stress, use of non-steroidal anti-inflammatory or some antidepressant drugs, smoking, use of cocaine, caffeine and alcohol abuse, and obesity \[[@pntd.0008103.ref019]--[@pntd.0008103.ref029]\]. Specifically, 15% of early abortions and 66% of late abortions are attributed to infections \[[@pntd.0008103.ref030], [@pntd.0008103.ref031]\]. *T*. *gondii*, *Toxocara cati*, *Toxocara canis*, *Plasmodium falciparum*, *Escherichia coli*, *Listeria monocytogenes*, *Brucella* species, *Klebsiella pneumonia*, *Rubella*, *Cytomegalovirus*, *Varicella---Zoster Virus*, human immunodeficiency virus, and human papillomavirus are the most common causes of intrauterine infections \[[@pntd.0008103.ref032], [@pntd.0008103.ref033]\]. Congenital infections, such as CT, are the main causes of miscarriage \[[@pntd.0008103.ref033]\]. Habitual abortion or recurrent miscarriage is the three consecutive pregnancy loss prior to 20 weeks from the last menstrual period \[[@pntd.0008103.ref017]\]. The common causes of habitual abortion include untreated hypothyroidism \[[@pntd.0008103.ref034]\], parental chromosomal abnormalities \[[@pntd.0008103.ref035]\], certain uterine anatomic abnormalities \[[@pntd.0008103.ref036]\], uncontrolled diabetes mellitus \[[@pntd.0008103.ref037]\], immunologic abnormalities \[[@pntd.0008103.ref038]\], infections \[[@pntd.0008103.ref039]\], and environmental factors \[[@pntd.0008103.ref040]\]. The prevalence of *T*. *gondii* infection in pregnant women varies significantly across different continents and countries around the world. Seroprevalence of *T*. *gondii* is reported to be high in Europe, up to 54% in Southern European countries, whereas this value was found to be within 18.5%-92.5% in sub-Saharan Africa \[[@pntd.0008103.ref041], [@pntd.0008103.ref042]\]. Given the important role of *T*. *gondii* infection in abortion and indefinite rate of *T*. *gondii*-associated abortion around the world, the present study aimed to determine the rate of seroprevalence of anti-*T*. *gondii* antibodies among women who had abortion or a history of abortion, and evaluate the relationship between seroprevalence of anti-*T*. *gondii* antibodies and abortion in women.

Methods {#sec006}
=======

Design and protocol registration {#sec007}
--------------------------------

A protocol was registered with PROSPERO (No. CRD42019124531) and published and the methods are briefly reported here \[[@pntd.0008103.ref043]\]. We used the preferred reporting items for systematic reviews and meta-analysis guidelines for the performance of this study ([S1 Table](#pntd.0008103.s001){ref-type="supplementary-material"}) \[[@pntd.0008103.ref044]\].

Search strategy {#sec008}
---------------

A literature search was performed using the following electronic databases: PubMed, Scopus, EMBASE, ProQuest, ScienceDirect, Web of Science, and Google Scholar search engine from inception until 25^th^ of April 2019. Search terms are applied alone or in combination as follows: (*Toxoplasma gondii* OR *T*. *gondii* OR toxoplasmosis) AND (abortion OR miscarriage OR fetal loss) AND pregnant women. In addition, the search was restricted to English language articles; therefore, published articles in non-English languages and unpublished studies were not investigated. Moreover, citation lists of relevant papers were checked.

Inclusion and exclusion criteria {#sec009}
--------------------------------

Inclusion criteria entailed English language articles evaluating the effects of *T*. *gondii* on abortion only among human subjects in cross-sectional and case-control studies. On the other hand, we excluded non-original papers (reviews, systematic reviews, editorials or letters), and conference papers. Also, the studies that *T*. *gondii* infection was diagnosed by molecular methods in women who had spontaneous abortion, paraffin-embedded blocks and placenta tissues were excluded from our study.

Study selection and data extraction {#sec010}
-----------------------------------

All retrieved articles were stored in EndNote X9 to organize the summaries. Search results were merged, duplicates were removed automatically and all the titles and abstracts and identified relevant articles were independently scanned by two team members ([Fig 1](#pntd.0008103.g001){ref-type="fig"}). Two reviewers independently extracted the data using a standardized form. The extracted variables included the name of the first author, year of publication, location of the study, diagnostic method, serological results, number of seropositive cases, as well as the age of the participants.

![Flow diagram of the study design process.](pntd.0008103.g001){#pntd.0008103.g001}

Quality assessment {#sec011}
------------------

The quality of the articles was assessed independently in terms of selection, comparability, and exposure. Quality was scored using the Newcastle-Ottawa Scales (NOS) \[[@pntd.0008103.ref045]\]. The quality scale was within the range of 0--9 points with a score of ≤ 3 representing a low-quality study. On the other hand, studies with a NOS score \> 6 in case-control and \> 5 in cross-sectional studies are considered high quality.

Statistical analysis {#sec012}
--------------------

The data were analyzed in Stata software (version 14; Stata Corp, College Station, TX, USA). The odds ratio (ORs) was used for this meta-analysis with 95% confidence intervals (CIs) to assess the relationship between seroprevalence of anti-*T*. *gondii* antibodies and abortion in women who had spontaneous abortion. Moreover, the pooled seroprevalence of anti-*T*. *gondii* antibodies was calculated in women with either a recent abortion or a history of abortion. In the forest plots, OR \> 1 denotes the positive effect of *T*. *gondii* on abortion, whereas an OR \< 1 is indicative of the protective effect of *T*. *gondii* on abortion. In addition, I^2^ statistics were applied to represent the heterogeneity index \[[@pntd.0008103.ref046]\]. Only when I^2^ \> 50%, the heterogeneity was considered significant. Publication bias was evaluated through Egger's test and it was considered significant when P-value was less than 0.05 \[[@pntd.0008103.ref047]\]. Additionally, the sensitivity analysis test was performed by removing the effect of each study on the overall results. In addition, the method of "trim and fill" has been used for a comprehensive evaluation of the possible effects of publication bias. The subgroup analysis and meta-regression test were conducted according to the diagnostic methods and type of study.

Results {#sec013}
=======

Study identification and selection {#sec014}
----------------------------------

A total of 35105 publications were identified and archived in EndNote (version X9) to organize the resources used in the research process. Duplicates were removed by automation followed by a manual duplicate search. The duplication search included a comparison of the authors' name, journals name, year of publication, volume number, issue number, page number, and the titles. In the next step, the titles and abstracts of full texts were independently reviewed by two researchers (TN and ZH). Finally, 244 papers were selected for the accurate evaluation of full texts out of which 72 papers were included in the systematic review. One study was not analyzed because it did not accurately quantify the number of IgM and IgG positive cases separately \[[@pntd.0008103.ref048]\], and its data were only systematically presented; therefore, 71 papers were included in the meta-analysis. Eight articles were related to the seroprevalence of anti-*T*. *gondii* antibodies in women who had spontaneous abortion in present pregnancy \[[@pntd.0008103.ref049]--[@pntd.0008103.ref056]\]. Moreover, serologic methods were used in six of these studies \[[@pntd.0008103.ref049]--[@pntd.0008103.ref052], [@pntd.0008103.ref055], [@pntd.0008103.ref056]\]. Two out of 8 articles used both serological and molecular methods in the diagnosis of *T*. *gondii* \[[@pntd.0008103.ref053], [@pntd.0008103.ref054]\]. The seroprevalence of anti-*T*. *gondii* antibodies in women who had a history of abortion (one or more times) was investigated in 40 articles. In addition, 60 articles were reviewed to estimate the relationship between seroprevalence of anti-*T*. *gondii* antibodies and abortion, out of which 35 articles were cross-sectional studies that examined the seroprevalence of anti-*T*. *gondii* antibodies in women who had a history of abortion; however, it was possible to calculate the ORs for them due to the nature of the studies. Therefore, they were also used to evaluate the relationship between seroprevalence of anti-*T*. *gondii* antibodies and abortion. [Fig 1](#pntd.0008103.g001){ref-type="fig"} demonstrates the process of articles screening and selection.

General characteristics of included studies {#sec015}
-------------------------------------------

General characteristics of included studies are depicted in Tables [1](#pntd.0008103.t001){ref-type="table"}--[3](#pntd.0008103.t003){ref-type="table"}. These studies which were published between 1971 and 2019 included 25 case-control and 47 cross-sectional studies. As shown in the Tables [1](#pntd.0008103.t001){ref-type="table"}--[3](#pntd.0008103.t003){ref-type="table"}, various studies have used the different diagnostic methods, such as enzyme-linked immunosorbent assay (ELISA), direct agglutination test (DAT), complement fixation test (CFT), latex agglutination test (LAT), indirect haemagglutination (IHA), haemagglutination (HA), indirect immunofluorescence assay (IFA), enzyme immunoassay (EIA), lateral flow immunoassay (LFIA), avidity test, Remington test, mini VIDAS technique, and one step advanced quality. Participants in the majority of articles were ascertained by ELISA (50 studies). Some studies used two or more diagnostic methods for *T*. *gondii* infection. It is noted that most researchers performed the tests using commercial kits and some of them used in house tests.

10.1371/journal.pntd.0008103.t001

###### Characteristics of the included studies for seroprevalence of anti-*T*. *gondii* antibodies in women who had a history of abortion.
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  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  First author                                         Publication year   Place of study         Type of study   Method (s)          Test          Sample size (n)   IgG+ n (%)    IgM+ n (%)    Age (years)
  ---------------------------------------------------- ------------------ ---------------------- --------------- ------------------- ------------- ----------------- ------------- ------------- ---------------
  Kimball, 1971 \[[@pntd.0008103.ref055]\]             1971               USA                    Cs              DAT\                IgG\          941               355 (37.72)   \--           \--
                                                                                                                 CFT                 IgM                                                         

  Stray-Pedersen, 1979 \[[@pntd.0008103.ref057]\]      1979               Norway                 Cs              DAT\                IgG           2048              279 (13.62)   \--           ≥ 35
                                                                                                                 IFA                                                                             

  Decavalas, 1990 \[[@pntd.0008103.ref058]\]           1990               Greece                 Cs              IFA for IgG\        IgG\          126               66 (52.38)    0 (0)         \--
                                                                                                                 Remington for IgM   IgM                                                         

  Singh, 1998 \[[@pntd.0008103.ref059]\]               1998               United Arab Emirates   Cs              IFA                 IgG\          1823              547 (30)      3 (0.16)      \--
                                                                                                                                     IgM                                                         

  Qublan, 2002 \[[@pntd.0008103.ref060]\]              2002               Amman                  Cs              IFA                 IgG\          104               64 (61.53)    \--           15--46
                                                                                                                                     IgM                                                         

  Elnahas, 2003 \[[@pntd.0008103.ref005]\]             2003               Sudan                  Cs              ELISA               IgG\          129               46 (35.65)    \--           \--
                                                                                                                                     IgM                                                         

  Nissapatorn, 2003 \[[@pntd.0008103.ref061]\]         2003               Malaysia               Cs              ELISA               IgG\          14                10 (71.42)    \--           15--44
                                                                                                                                     IgM                                                         

  Chopra, 2004 \[[@pntd.0008103.ref062]\]              2004               India                  Cs              ELISA               IgM           118                             61 (51.69)    15--45

  Ertug, 2005 \[[@pntd.0008103.ref063]\]               2005               Turkey                 Cs              ELISA\              IgG           90                33 (36.7)     \--           15--40
                                                                                                                 IFA\                                                                            
                                                                                                                 DAT\                                                                            
                                                                                                                 Avidity test                                                                    

  Barbosa, 2009 \[[@pntd.0008103.ref064]\]             2009               Brazil                 Cs              EIA                 IgG\          71                46 (64.78)    \--           13--40
                                                                                                                                     IgM                                                         

  Nijem, 2009 \[[@pntd.0008103.ref065]\]               2009               Palestine              Cs              ELISA               IgG\          76                25 (32.89)    14 (18.42)    16--43
                                                                                                                                     IgM                                                         

  Mousa, 2011 \[[@pntd.0008103.ref066]\]               2011               Libya                  Cs              ELISA               IgG\          117               55 (47.1)     \--           18--44
                                                                                                                                     IgM                                                         

  Drueish, 2011 \[[@pntd.0008103.ref067]\]             2011               Iraq                   Cs              ELISA               IgG\          122               25 (20.49)    17 (13.93)    15--45
                                                                                                                                     IgM                                                         

  Pavlinová, 2011 \[[@pntd.0008103.ref032]\]           2011               Slovak Republic        Cs              EIA                 IgG\          221               93 (42.1)     4 (1.8)       31.3 ± 5.6
                                                                                                                                     IgM                                                         

  Jasim, 2011 \[[@pntd.0008103.ref068]\]               2011               Iraq                   Cs              ELISA               IgG\          162               144 (88.88)   148 (91.35)   15--65
                                                                                                                                     IgM                                                         

  Nissapatorn, 2011 \[[@pntd.0008103.ref069]\]         2011               Thailand               Cs              ELISA               IgG\          147               43 (29.25)    \--           15--45
                                                                                                                                     IgM                                                         

  Hajsoleimani, 2012 \[[@pntd.0008103.ref006]\]        2012               Iran                   Cs              ELISA               IgG\          423               159 (37.6)    \--           \> 30
                                                                                                                                     IgM                                                         

  Malarvizhi, 2012 \[[@pntd.0008103.ref070]\]          2012               India                  Cs              ELISA               IgG\          67                12 (17.91)    (11.94)       \> 40
                                                                                                                                     IgM                                                         

  Padmavathy, 2013 \[[@pntd.0008103.ref071]\]          2013               India                  Cs              ELISA               IgG\          47                27 (57.44)    4 (8.51)      19.36
                                                                                                                                     IgM                                                         

  Ebrahimzadeh, 2013 \[[@pntd.0008103.ref072]\]        2013               Iran                   Cs              ELISA               IgG\          71                17 (23.94)    \--           14--44
                                                                                                                                     IgM                                                         

  Moura, 2013 \[[@pntd.0008103.ref073]\]               2013               Brasil                 Cs              IFA\                IgG\          92                59 (64.13)    \--           14--45
                                                                                                                 ELISA               IgM                                                         

  Babaie, 2013 \[[@pntd.0008103.ref074]\]              2013               Iran                   Cs              ELISA               IgG\          82                31 (37.80)    \--           16--47
                                                                                                                                     IgM                                                         

  Chintapalli, 2013 \[[@pntd.0008103.ref075]\]         2013               India                  Cs              ELISA               IgG\          20                15 (75)       5 (25)        15--34
                                                                                                                                     IgM                                                         

  Alvarado-Esquivel, 2014 \[[@pntd.0008103.ref076]\]   2014               Mexico                 Cs              EIA                 IgG\          326               22 (6.7)      2 (0.6)       35.57 ± 12.43
                                                                                                                                     IgM                                                         

  Almushait, 2014 \[[@pntd.0008103.ref077]\]           2014               Saudi Arabia           Cs              ELISA               IgG\          162               71 (43.82)    12 (7.40)     16--41
                                                                                                                                     IgM                                                         

  Abedi, 2015 \[[@pntd.0008103.ref078]\]               2015               Iran                   Cs              ELISA               IgG           300               111 (37)      \--           16--39

  Awoke, 2015 \[[@pntd.0008103.ref042]\]               2015               Ethiopia               Cs              LAT                 IgG\          95                29 (30.5)     \--           15--44
                                                                                                                                     IgM                                                         

  Gelaye, 2015 \[[@pntd.0008103.ref079]\]              2015               Ethiopia               Cs              LAT                 IgG\          71                62 (87.3)     \--           15--35
                                                                                                                                     IgM                                                         

  Alvarado-Esquivel, 2015 \[[@pntd.0008103.ref080]\]   2015               Mexico                 Cs              EIA                 IgG\          43                2 (4.7)       \--           16--50
                                                                                                                                     IgM                                                         

  Anubhuti, 2015 \[[@pntd.0008103.ref081]\]            2015               India                  Cs              LFIA                IgG\          60                12 (20)       0 (0)         21--35
                                                                                                                                     IgM                                                         

  Mohamed, 2016 \[[@pntd.0008103.ref082]\]             2016               Saudi Arabia           Cs              EIA                 IgG\          126               23 (18.25)    0 (0)         16--40
                                                                                                                                     IgM                                                         

  Mohaghegh, 2016 \[[@pntd.0008103.ref083]\]           2016               Iran                   Cs              ELISA               IgG\          35                35 (100)      \--           18--45
                                                                                                                                     IgM                                                         

  Imam, 2016 \[[@pntd.0008103.ref084]\]                2016               Egypt                  Cs              ELISA               IgG\          112               22 (19.6)     \--           15--49
                                                                                                                                     IgM                                                         

  Nazir, 2017 \[[@pntd.0008103.ref085]\]               2017               Pakistan               Cs              ELISA               IgG           93                31 (33.33)    \--           ≥ 36

  Yasmeen, 2017 \[[@pntd.0008103.ref086]\]             2017               India                  Cs              ELISA               IgG\          39                10 (25.6)     \--           18--35
                                                                                                                                     IgM                                                         

  Negero, 2017 \[[@pntd.0008103.ref041]\]              2017               Ethiopia               Cs              LAT                 IgG\          207               176 (83.8)    \--           15--34
                                                                                                                                     IgM                                                         

  Matin, 2017 \[[@pntd.0008103.ref087]\]               2017               Iran                   Cs              ELISA\              IgG\          200               86 (43)       8 (4)         16--41
                                                                                                                 Nested-PCR          IgM                                                         

  Costa, 2018 \[[@pntd.0008103.ref088]\]               2018               Brazil                 Cs              ELISA               IgG\          89                64 (71.9)     \--           \> 19
                                                                                                                                     IgM                                                         

  Hafez Hassanain \[[@pntd.0008103.ref089]\]           2018               Egypt                  Cs              ELISA               IgG\          47                20 (42.5)     \--           15--44
                                                                                                                                     IgM\                                                        
                                                                                                                                     IgG avidity                                                 

  Rashno, 2019 \[[@pntd.0008103.ref090]\]              2019               Iran                   Cs              ELISA\              IgG\          6                 3 (50)        0 (0)         \--
                                                                                                                 PCR                 IgM                                                         
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Cs: cross-sectional, DAT: direct agglutination test, CFT: complement fixation test, LAT: latex agglutination test, ELISA: enzyme-linked immunosorbent assay, IFA: indirect immunofluorescence assay, EIA: enzyme immunoassay, LFIA: lateral flow immunoassay, PCR: polymerase chain reaction, IgG: immunoglobulin G, IgM: immunoglobulin M

10.1371/journal.pntd.0008103.t002

###### Characteristics of the included studies for seroprevalence of anti-*T*. *gondii* antibodies in women who had abortion in present pregnancy.
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  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  First author                                          Publication year   Place of study   Type of study   Method (s)             Test   Sample size (n)   IgG+ n (%)   IgM+ n (%)   Age (years)
  ----------------------------------------------------- ------------------ ---------------- --------------- ---------------------- ------ ----------------- ------------ ------------ -------------
  Kimball, 1971 \[[@pntd.0008103.ref055]\]              1971               USA              Cs              DAT\                   IgG\   260               109 (41.9)   0 (0)        \--
                                                                                                            CFT                    IgM                                                

  Sanghi, 1997 \[[@pntd.0008103.ref052]\]               1997               United Kingdom   Cs              LAT\                   IgG\   85                0 (0)        0 (0)        \--
                                                                                                            ELISA                  IgM                                                

  Hadi, 2011 \[[@pntd.0008103.ref056]\]                 2011               Iraq             Cs              Mini VIDAS technique   IgG\   190               11 (5.78)    24 (12.63)   15--45
                                                                                                                                   IgM                                                

  Amin, 2012 \[[@pntd.0008103.ref049]\]                 2012               Iran             Cs              ELISA                  IgG\   264               99 (37.5)    21 (8.0)     14--57
                                                                                                                                   IgM\                                               
                                                                                                                                   IgA                                                

  Tammam, 2013 \[[@pntd.0008103.ref050]\]               2013               Egypt            Cs              ELISA                  IgG\   76                35 (46.1)    14 (18.4)    19--36
                                                                                                                                   IgM                                                

  Vado-Solis, 2013 \[[@pntd.0008103.ref053]\]           2013               Mexico           Cs              ELISA\                 IgG\   100               32 (32)      2 (2)        25.3 ± 7.3
                                                                                                            PCR                    IgM                                                

  Hernández-Cortazar, 2016 \[[@pntd.0008103.ref054]\]   2016               Mexico           Cs              ELISA\                 IgG\   161               95 (59)      6 (3.72)     \--
                                                                                                            Q-PCR\                 IgM                                                
                                                                                                            Nested PCR                                                                

  El Aal, 2018 \[[@pntd.0008103.ref051]\]               2018               Egypt            Cs              ELISA\                 IgG\   139               62 (44.6)    \--          21--34
                                                                                                            Q-PCR\                 IgM                                                
                                                                                                            LAMP                                                                      
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Cs: cross-sectional, DAT: direct agglutination test, CFT: complement fixation test, LAT: latex agglutination test, ELISA: enzyme-linked immunosorbent assay, PCR: polymerase chain reaction, Q-PCR: quantitative PCR, LAMP: loop-mediated isothermal amplification, IgG: immunoglobulin G, IgM: immunoglobulin M

10.1371/journal.pntd.0008103.t003

###### Description of the studies included looking for an association between seroprevalence of anti-*T*. *gondii* antibodies and abortion.
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  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  First author                                          Publication year   Place of study    Type of study   Method (s)                  Test              N      Case (n)   Case & IgG+ (n, %)   Case & IgM+ (n, %)   Control (n)   Control & IgG+ (n, %)   Control & IgM+ (n, %)   Age (years)
  ----------------------------------------------------- ------------------ ----------------- --------------- --------------------------- ----------------- ------ ---------- -------------------- -------------------- ------------- ----------------------- ----------------------- --------------------
  Kimball, 1971 \[[@pntd.0008103.ref055]\]              1971               USA               Cs              DAT\                        IgG\              4832   941        355 (37.72)          \--                  3891          1206 (31)               \--                     P: \--\
                                                                                                             CFT                         IgM                                                                                                                                         C: 25

  Stray-Pedersen, 1977 \[[@pntd.0008103.ref091]\]       1977               Norway            Cc              DAT\                        IgG               216    157        39 (25)              \--                  59            11 (19)                 \--                     P: 29.4\
                                                                                                             IFA\                                                                                                                                                                    C: 29.4
                                                                                                             CFT                                                                                                                                                                     

  Lolis, 1978 \[[@pntd.0008103.ref092]\]                1978               Greece            Cc              HA\                         IgG\              232    152        62 (40.8)            \--                  80            10 (12.5)               \--                     \--
                                                                                                             IFA                         IgM IgA                                                                                                                                     

  Decavalas, 1990 \[[@pntd.0008103.ref058]\]            1990               Greece            Cs              IFA for IgG\                IgG IgM           303    126        66 (52.38)           0 (0)                177           88 (49.71)              0 (0)                   P: 27.8\
                                                                                                             Remington for IgM                                                                                                                                                       C: 25.9

  Galvan Ramirez, 1995 \[[@pntd.0008103.ref093]\]       1995               Mexico            Cc              ELISA                       IgG IgM           155    105        48 (44.9)            35 (33.3)            50            13(26.01)               1 (1.9)                 P: 32.3 ± 7\
                                                                                                                                                                                                                                                                                     C: 31.7 ± 7.1

  Sahwi, 1995 \[[@pntd.0008103.ref094]\]                1995               Egypt             Cc              IHA                         IgG IgM           140    100        37 (37)              19 (19)              40            4 (10)                  3 (7.5)                 P: 30 ± 5.975\
                                                                                                                                                                                                                                                                                     C: 28 ± 5.236

  Djurkovic-Djakovic, 1995 \[[@pntd.0008103.ref095]\]   1995               Yogoslavi         Cc              DAT                         IgG IgM           2315   1747       570 (32.62)          94 (5.38)            568           193 (33.97)             27 (4.75)               14--45

  Al Hamdani, 1997 \[[@pntd.0008103.ref096]\]           1997               Iraq              Cc              IHA\                        IgG IgM           200    81         15 (18.5)            \--                  119           7 (5.9)                 \--                     P: 29 ± 7.9\
                                                                                                             IFA                                                                                                                                                                     C: 27 ±6.93

  Zargar, 1998 \[[@pntd.0008103.ref097]\]               1998               India             Cc              ELISA                       IgM               454    285        \--                  141 (49.47)          169           \--                     15 (8.87)               P: 27.73 ± 4.57\
                                                                                                                                                                                                                                                                                     C: 28.59 ±5.13

  Qublan, 2002 \[[@pntd.0008103.ref060]\]               2002               Amman             Cs              IFA                         IgG IgM           280    104        64 (61.53)           \--                  176           68 (38.63)              \--                     15--46

  Elnahas, 2003 \[[@pntd.0008103.ref005]\]              2003               Sudan             Cs              ELISA                       IgG IgM           487    129        46 (35.65)           \--                  358           120 (33.51)             \--                     \--

  Nissapatorn, 2003 \[[@pntd.0008103.ref061]\]          2003               Malaysia          Cs              ELISA                       IgG IgM           200    14         10 (71.42)                                186           88 (47.3)                                       15--44

  Chopra, 2004 \[[@pntd.0008103.ref062]\]               2004               India             Cs              ELISA                       IgM               218    118                             61 (51.69)           100                                   0 (0)                   15--45

  Nimri, 2004 \[[@pntd.0008103.ref098]\]                2004               France            Cc              ELISA\                      IgG IgM           248    148        80 (54.0)            4 (2.7)              100           12 (12.0)               0 (0)                   P: 28\
                                                                                                             Nested PCR                                                                                                                                                              C: 28

  Ertug, 2005 \[[@pntd.0008103.ref063]\]                2005               Turkey            Cs              ELISA\                      IgG               357    90         33 (36.7)            \--                  267           78 (29.2)               \--                     15--40
                                                                                                             IFA\                                                                                                                                                                    
                                                                                                             DAT\                                                                                                                                                                    
                                                                                                             Avidity Test                                                                                                                                                            

  Surpam, 2006 \[[@pntd.0008103.ref099]\]               2006               India             Cc              ELISA                       IgM               119    44         \--                  12 (27.27)           75            \--                     1 (1.33)                20--38

  Sebastian, 2008 \[[@pntd.0008103.ref100]\]            2008               India             Cc              ELISA                       IgG IgM           101    71                              36 (50.7)            30            \--                     6 (20)                  15--34

  Al-Saeed, 2008 \[[@pntd.0008103.ref101]\]             2008               Iraq              Cc              LAT                         IgG IgM           140    120        50 (41.7)            \--                  20            0 (0)                   \--                     \--

  Barbosa, 2009 \[[@pntd.0008103.ref064]\]              2009               Brazil            Cs              EIA                         IgG IgM           190    71         46 (64.78)           \--                  119           81 (68.06)              \--                     13--40

  Nijem, 2009 \[[@pntd.0008103.ref065]\]                2009               Palestine         Cs              ELISA                       IgG IgM           204    76         25 (32.89)           14 (18.42)           128           32 (25)                 22 (17.18)              16--43

  AL--Taie, 2010 \[[@pntd.0008103.ref102]\]             2009               Iraq              Cc              ELISA                       IgM               88     38         \--                  15 (39.4)            50            \--                     6 (12)                  \> 41

  Hassan, 2009 \[[@pntd.0008103.ref103]\]               2009               Iraq              Cc              ELISA                       IgG IgM           119    96         7 (7.29)             20 (20.83)           23            2 (8.7)                 0 (0)                   23.9--28.5

  Drueish, 2011 \[[@pntd.0008103.ref067]\]              2011               Iraq              Cs              ELISA                       IgG IgM           177    122        25 (20.49)           17 (13.93)           50            12(24)                  0 (0)                   15--45

  Pavlinová, 2011 \[[@pntd.0008103.ref032]\]            2011               Slovak Republic   Cs              EIA                         IgG IgM           537    221        93 (42.1)            4 (1.8)              179           45 (25.1)               5 (2.8)                 P: 31.3 ± 5.6\
                                                                                                                                                                                                                                                                                     C: 29.4 ± 5.6

  Jasim, 2011 \[[@pntd.0008103.ref068]\]                2011               Iraq              Cs              ELISA                       IgG IgM           300    162        144 (88.88)          148 (91.35)          138           123 (89.13)             122 (88.40)             15--65

  Mousa, 2011 \[[@pntd.0008103.ref066]\]                2011               Libya             Cs              ELISA                       IgG IgM           143    117        55 (47.1)            \--                  26            9 (34.6)                \--                     18--44

  Nissapatorn, 2011 \[[@pntd.0008103.ref069]\]          2011               Thailand          Cs              ELISA                       IgG IgM           640    147        43 (29.25)           \--                  493           138 (28)                \--                     15--45

  Hajsoleimani, 2012 \[[@pntd.0008103.ref006]\]         2012               Iran              Cs              ELISA                       IgG IgM           500    423        159 (37.6)           \--                  77            30 (39)                 \--                     \> 30

  Malarvizhi, 2012 \[[@pntd.0008103.ref070]\]           2012               India             Cs              ELISA                       IgG IgM           232    67         12 (17.91)           8 (11.94)            165           11 (4.74)               1 (0.43)                \> 40

  Elamin, 2012 \[[@pntd.0008103.ref104]\]               2012               Saudi Arabia      Cc              ELISA\                      IgG IgM           188    94         33 (35.1)            5 (15.2)             94            37 (39.4)               6 (16.2)                \--
                                                                                                             PCR                                                                                                                                                                     

  Ebrahimzadeh, 2013 \[[@pntd.0008103.ref072]\]         2013               Iran              Cs              ELISA                       IgG IgM           221    71         17 (23.94)           \--                  150           51 (34)                 \--                     14--44

  Babaie, 2013 \[[@pntd.0008103.ref074]\]               2013               Iran              Cs              ELISA                       IgG IgM           419    82         31 (37.80)           \--                  337           113 (33.5)              \--                     16--47

  Moura, 2013 \[[@pntd.0008103.ref073]\]                2013               Brazil            Cs              IFA\                        IgG IgM           400    92         59 (64.13)           \--                  308           175 (56.81)             \--                     14--45
                                                                                                             ELISA                                                                                                                                                                   

  Chintapalli, 2013 \[[@pntd.0008103.ref075]\]          2013               India             Cs              ELISA                       IgG IgM           32     20         15 (75)              5 (25)               12            1 (8.33)                1 (8.33)                15--34

  Hussan, 2013 \[[@pntd.0008103.ref105]\]               2013               Iraq              Cc              ELISA                       IgG IgM           255    210        46 (22)              32 (15.23)           45            3 (6.66)                0 (0)                   \--

  Abou-Gabal, 2013 \[[@pntd.0008103.ref048]\]           2013               Egypt             Cc              One step advanced quality   IgG IgM           80     40         \--                  \--                  40            \--                     \--                     P: 33.13 ± 10.341\
                                                                                                                                                                                                                                                                                     C: 33.05 ± 8.941

  Siddiqui, 2014 \[[@pntd.0008103.ref106]\]             2014               India             Cc              ELISA                       IgG IgM           63     48         \--                  17 (35.4)            15            \--                     0 (0)                   \> 30

  Almushait, 2014 \[[@pntd.0008103.ref077]\]            2014               Saudi Arabia      Cs              ELISA                       IgG IgM           487    162        71 (43.82)           12 (7.40)            325           118 (36.3)              18 (5.5)                16--41

  Sultana, 2014 \[[@pntd.0008103.ref107]\]              2014               Bangladesh        Cc              ELISA                       IgG IgM           91     46         8 (17.4)             7 (15.2)             45            4 (8.9)                 0 (0)                   P: 24.43 ± 4.17\
                                                                                                                                                                                                                                                                                     C: 24.56 ±4.36

  Abbas, 2014 \[[@pntd.0008103.ref108]\]                2014               Iraq              Cc              ELISA                       IgG IgM           130    100        42 (42)              12 (12)              30            0 (0)                   0 (0)                   \--

  Awoke, 2015 \[[@pntd.0008103.ref042]\]                2015               Ethiopia          Cs              LAT                         IgG IgM           384    95         29 (30.5)            \--                  289           42 (14.5)               \--                     15--44

  Gelaye, 2015 \[[@pntd.0008103.ref079]\]               2015               Ethiopia          Cs              LAT                         IgG IgM           288    71         62 (87.3)            \--                  217           184 (84.8)              \--                     15--35

  Saki, 2015 \[[@pntd.0008103.ref109]\]                 2015               Iran              Cc              ELISA                       IgG IgM           260    130        32 (24.6)            1 (0.76)             130           28 (21.5)               0 (0)                   \--

  Kamal, 2015 \[[@pntd.0008103.ref110]\]                2015               Egypt             Cc              ELISA                       IgG IgM           149    29         18 (62.0)            \--                  120           8 (6.66)                \--                     18--40

  Anubhuti, 2015 \[[@pntd.0008103.ref081]\]             2015               India             Cs              LFIA                        IgG IgM           120    60         12 (20)              0 (0)                60            3 (5)                   0 (0)                   21--35

  Alvarado-Esquivel, 2015 \[[@pntd.0008103.ref080]\]    2015               Mexico            Cs              EIA                         IgG IgM           150    43         2 (4.7)              \--                  107           12 (11.2)               \--                     16--50

  Ghasemi, 2016 \[[@pntd.0008103.ref111]\]              2016               Iran              Cc              ELISA\                      IgG IgM           192    82         22 (26.8)            3 (3.6)              110           29 (26.4)               1 (0.9)                 P: 28.29\
                                                                                                             PCR                                                                                                                                                                     C: 28.58

  Mohaghegh, 2016 \[[@pntd.0008103.ref083]\]            2016               Iran              Cs              ELISA                       IgG IgM           350    35         35 (100)             \--                  315           75 (23.8)               \--                     18--45

  Mohamed, 2016 \[[@pntd.0008103.ref082]\]              2016               Saudi Arabia      Cs              ELISA                       IgG IgM           326    126        23 (18.25)           0 (0)                200           46 (23)                 4 (2)                   16--40

  Nazir, 2017 \[[@pntd.0008103.ref085]\]                2016               Pakistan          Cs              ELISA                       IgG               403    93         31 (33.33)           \--                  310           40 (12.90)              \--                     ≥ 36

  Imam, 2016 \[[@pntd.0008103.ref084]\]                 2016               Egypt             Cs              ELISA                       IgG IgM           138    112        22 (19.6)            \--                  26            4 (15.4)                \--                     15--49

  Rasti, 2016 \[[@pntd.0008103.ref112]\]                2016               Iran              Cc              ELISA                       IgG IgM           179    81         22 (27.2)            1 (1.2)              98            28 (28.6)               2 (2)                   P: 28.2\
                                                                                                                                                                                                                                                                                     C: 28.6

  Yasmeen, 2017 \[[@pntd.0008103.ref086]\]              2017               India             Cs              ELISA                       IgG IgM           251    39         10 (25.6)            \--                  212           43 (20.3)               \--                     18--35

  Negero, 2017 \[[@pntd.0008103.ref041]\]               2017               Ethiopia          Cs              LAT                         IgG IgM           369    207        176 (83.8)           \--                  162           34 (16.2)               \--                     15--34

  Matin, 2017 \[[@pntd.0008103.ref087]\]                2017               Iran              Cs              ELISA Nested-PCR            IgG IgM           200    58         31 (53.44)           0 (0)                142           55 (38.73)              8 (5.63)                16--41

  Costa, 2018 \[[@pntd.0008103.ref088]\]                2018               Brazil            Cs              ELISA                       IgG IgM           352    89         64 (71.9)            \--                  263           189 (71.8)              \--                     \> 19

  Çakmak, 2018 \[[@pntd.0008103.ref113]\]               2018               Turkey            Cc              ELISA                       IgG IgM           1240   412        125 (30.6)           27 (6.6)             828           157 (19.2)              35 (4.2)                P: 27.6 ± 11.4\
                                                                                                                                                                                                                                                                                     C: 29.1 ± 9.87

  Hafez Hassanain, 2018 \[[@pntd.0008103.ref089]\]      2018               Egypt             Cs              ELISA                       IgG\              388    47         20 (42.5)            \--                  341           59 (17.3)               \--                     15--44
                                                                                                                                         IgM IgG avidity                                                                                                                             

  Rashno, 2019 \[[@pntd.0008103.ref090]\]               2019               Iran              Cs              ELISA\                      IgG IgM           98     6          3 (50)               0 (0)                92            31 (33.69)              0 (0)                   \--
                                                                                                             PCR                                                                                                                                                                     

  Kheirandish, 2019 \[[@pntd.0008103.ref114]\]          2019               Iran              Cc              ELISA                       IgG IgM           480    240        114 (47.5)           8 (3.3)              240           111 (46.3)              1 (0.4)                 P: 27 ± 6.499\
                                                                                                                                                                                                                                                                                     C: 27.01 ± 6.459
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Cs: cross-sectional, CC: case-control, DAT: direct agglutination test, CFT: complement fixation test, LAT: latex agglutination test, ELISA: enzyme-linked immunosorbent assay, IHA: indirect haemagglutination, HA: haemagglutination, IFA: indirect immunofluorescence assay, EIA: enzyme immunoassay, LFIA: lateral flow immunoassay, PCR: polymerase chain reaction, IgG: immunoglobulin G, IgM: immunoglobulin M, Case: women who had abortion, Control: women who had not abortion

In addition, the included articles in the present meta-analysis showed an acceptable quality (i.e., ≥ 3 for cross-sectional studies and ≥ 4 for case-control studies). [S2 Table](#pntd.0008103.s002){ref-type="supplementary-material"} represents the quality score of different eligible studies.

Seroprevalence of anti-*T*. *gondii* antibodies in women who had a history of abortion {#sec016}
--------------------------------------------------------------------------------------

A total of 9004 women who had a history of abortion were investigated for the seroprevalence of anti*-T*. *gondii* IgG antibody in 39 articles, out of which 2930 were positive using several serological methods. In addition, 16 studies entailing 3662 women who had spontaneous abortion were reviewed for the seroprevalence of anti-*T*. *gondii* IgM antibody out of which 286 women were seropositive. According to forest plot diagram in [Fig 2](#pntd.0008103.g002){ref-type="fig"} and [S1 Fig](#pntd.0008103.s003){ref-type="supplementary-material"}, the pooled seroprevalence of anti- *T*. *gondii* IgG and IgM antibodies in women who had a history of abortion based on a random effects model was estimated at 43% (95% CI: 27%-60%) and 3% (95% CI: 3%-4%), respectively. Furthermore, I^2^ statistic revealed a significant heterogeneity among the studies (I^2^ = 99.87%, P = 0.00). Moreover, subgroup analysis results based on diagnostic methods showed that heterogeneity for ELISA and other methods (DAT, CFT, LAT, IFA, EIA, LFIA, and Remington test) were I^2^ = 99.53%, P = 0.00 and I^2^ = 99.22%, P = 0.00, respectively. In addition, heterogeneity between groups was P = 0.744 ([Fig 2](#pntd.0008103.g002){ref-type="fig"}).

![The reported seroprevalence of anti- *T*. *gondii* IgG antibody in women who had a history of abortion.\
The horizontal lines define the reported 95% confidence interval for the seroprevalence in each study, and the diamond below the graph shows the pooled seroprevalence.](pntd.0008103.g002){#pntd.0008103.g002}

Seroprevalence of anti*-T*. *gondii* antibodies in women who had abortion in present pregnancy {#sec017}
----------------------------------------------------------------------------------------------

A total number of 1275 women who had spontaneous abortion in present pregnancy were examined for the seroprevalence of anti- *T*. *gondii* antibodies using different serologic tests. 1275 serum samples in eight studies and 1136 serum samples of women who had abortion in present pregnancy in seven studies were evaluated for anti- *T*. *gondii* IgG and IgM antibodies using serologic tests out of which 443 and 67 cases were positive for anti- *T*. *gondii* IgG and IgM antibodies, respectively. The pooled seroprevalence rates of anti- *T*. *gondii* IgG and IgM antibodies in women who had abortion in present pregnancy using a random-effects model were determined to be 33% (95% CI: 17%-49%) and 1% (95% CI: 1%-2%), respectively ([Fig 3](#pntd.0008103.g003){ref-type="fig"} and [S2 Fig](#pntd.0008103.s004){ref-type="supplementary-material"}). The results of heterogeneity test in different studies for IgG and IgM antibodies were I^2^ = 99.14%, P = 0.00; I^2^ = 92.06%, P = 0.00, respectively.

![The reported seroprevalence of anti- *T*. *gondii* IgG antibody in women who had abortion in present pregnancy.](pntd.0008103.g003){#pntd.0008103.g003}

Relationship between anti-*T*. *gondii* IgG antibody and abortion {#sec018}
-----------------------------------------------------------------

A total of 53 studies entailing 8448 women who had spontaneous abortion and 13097 control individuals were evaluated in the current study. This meta-analysis included 34 cross-sectional studies evaluating anti-*T*. *gondii* IgG antibody and abortion with 4318 women who had spontaneous abortion (1889 positive for anti-*T*. *gondii* antibodies) and 10298 women as the control group (3404 positive for anti-*T*. *gondii* antibodies). Moreover, 19 case-control articles evaluating anti-*T*. *gondii* IgG antibody and abortion were entered into the meta-analysis including 4130 women who had spontaneous abortion (1370 positive for anti- *T*. *gondii* antibodies) and 2799 controls (657 positive for anti- *T*. *gondii* antibodies). As depicted in the forest plot diagram, the pooled ORs of the risk of anti-*T*. *gondii* IgG antibody investigated in women who had spontaneous abortion in cross-sectional and case-control studies were 1.65 (95% CI: 1.31--2.09) and 2.26 (95% CI: 1.56--3.28), respectively (Figs [4](#pntd.0008103.g004){ref-type="fig"} and [5](#pntd.0008103.g005){ref-type="fig"}). Additionally, the test of heterogeneity revealed significant heterogeneity among cross-sectional and case-control studies as I^2^ = 82.2%, P = 0.00 and I^2^ = 84.8%, P = 0.00, respectively. Publication bias was assessed using Egger's test in cross-sectional studies (P = 0.194) and no publication bias was observed ([S3 Fig](#pntd.0008103.s005){ref-type="supplementary-material"}). On the other hand, the results of Eggert's test were statistically significant in case-control studies (P = 0.007) ([S4 Fig](#pntd.0008103.s006){ref-type="supplementary-material"}). In addition, there was no change in the results of pooled random-effects analysis corrected by using "trim and fill" method ([S5 Fig](#pntd.0008103.s007){ref-type="supplementary-material"}). The robustness and reliability of the results of this meta-analysis were indicated by sensitivity analysis ([S6](#pntd.0008103.s008){ref-type="supplementary-material"} and [S7](#pntd.0008103.s009){ref-type="supplementary-material"} Figs). In order to improve the interpretation of the meta-analysis results, a meta-regression test was performed based on the type of study revealing the significant effect of type of study on the heterogeneity of the studies (P = 0.032).

![Forest plot diagram of cross-sectional studies showing IgG seropositivity rates of *T*. *gondii*.](pntd.0008103.g004){#pntd.0008103.g004}

![Forest plot diagram of case-control studies showing IgG seropositivity rates of *T*. *gondii*.](pntd.0008103.g005){#pntd.0008103.g005}

Relationship between anti-*T*. *gondii* IgM antibody and abortion {#sec019}
-----------------------------------------------------------------

A total of 29 papers were entered into the meta-analysis including 1132 women who had spontaneous abortion (269 positive for anti- *T*. *gondii* antibodies) and 1439 controls (198 positive for anti- *T*. *gondii* antibodies) in 10 cross-sectional studies, as well as 4077 women who had spontaneous abortion (489 positive for anti- *T*. *gondii* antibodies) and 2740 controls (104 positive for anti- *T*. *gondii* antibodies) in 19 case-control studies evaluating anti-*T*. *gondii* IgM antibody. The results of the meta-analysis indicated a common OR of the risk of anti-*T*. *gondii* IgM antibody 1.39 (95% CI: 0.61-3.15) in cross-sectional studies ([Fig 6](#pntd.0008103.g006){ref-type="fig"}) and 4.33 (95% CI: 2.42--7.76) in case-control ones ([Fig 7](#pntd.0008103.g007){ref-type="fig"}). Moreover, the results illustrated a significant heterogeneity in cross-sectional and case-control studies (I^2^ = 75.9%, P = 0.00 and I^2^ = 71.5%, P = 0.00), respectively.

![Forest plot diagram of cross-sectional studies showing IgM seropositivity rates of *T*. *gondii*.](pntd.0008103.g006){#pntd.0008103.g006}

![Forest plot diagram of case-control studies showing IgM seropositivity rates of *T*. *gondii*.](pntd.0008103.g007){#pntd.0008103.g007}

The results of Egger's test were not statistically significant in cross-sectional studies (P = 0.36), which indicates no publication bias. However, the funnel plot shows asymmetric pattern ([S8 Fig](#pntd.0008103.s010){ref-type="supplementary-material"}). Based on the results of "trim and fill" method, publication bias does not appear to have a significant impact on the results ([S9 Fig](#pntd.0008103.s011){ref-type="supplementary-material"}). On the other hand, the results of Egger's test were statistically significant in case-control studies (P = 0.02) ([S10 Fig](#pntd.0008103.s012){ref-type="supplementary-material"}). According to the results of "trim and fill" method, publication bias does not have a significant effect on the results of the pooled random-effects analysis ([S11 Fig](#pntd.0008103.s013){ref-type="supplementary-material"}). The results confirmed the reliability and stability of the present meta-analysis after the performance of sensitivity analyses ([S12](#pntd.0008103.s014){ref-type="supplementary-material"} and [S13](#pntd.0008103.s015){ref-type="supplementary-material"} Figs). In addition, we performed the meta-regression analysis based on the type of study suggesting type of study had no significant effect on the heterogeneity among the studies included in the present meta-analysis (P = 0.77).

Discussion {#sec020}
==========

Fetuses are at high risk of this parasite during acute infection due to *Toxoplasma*\'s ability to cross the placental barrier and infect the fetus before it can acquire immunity \[[@pntd.0008103.ref115]\]. This systematic review and meta-analysis investigated the seroprevalence of anti- *T*. *gondii* antibodies in women who had abortion in present pregnancy or a history of abortion and the relationship between the seroprevalence of anti- *T*. *gondii* antibodies and abortion. The obtained results indicated that the overall estimation for the prevalence of anti- *T*. *gondii* IgG antibodies in women who had a history of abortion (43%; 95% CI: 27%-60%) was higher than those with present abortion (33%; 95% CI: 17%-49%). According to Figs [2](#pntd.0008103.g002){ref-type="fig"} and [3](#pntd.0008103.g003){ref-type="fig"}, the highest and lowest seroprevalence rates of anti- *T*. *gondii* antibodies in women who had a history of abortion were related to the studies performed by Mohaghegh *et al*. as 100% (95% CI: 0--100%) \[[@pntd.0008103.ref083]\] and Alvarado-Esquivel *et al*. as 5% (95% CI: 1--15%) \[[@pntd.0008103.ref080]\]. Additionally, the highest and lowest seroprevalence rates of anti- *T*. *gondii* antibodies in women who had abortion in present pregnancy were observed in studies conducted by Hernández-Cortazar *et al*. as 59% (95% CI: 51--66%) \[[@pntd.0008103.ref054]\] and Sanghi *et al*. as 0% (95% CI: 0--4%) \[[@pntd.0008103.ref052]\]. IgG seropevalence is dependent on age and the risk of fetal loss increases after the age of 35 years. The risk of fetal loss is 9% in women aged 20--24 years and increases to 75% among women aged 45 and over. Because in the included articles the relationship of age and the seropositivity of *T*.*gondii* antibodies was not evaluated, we avoided the analysis of this main risk factor and this can be considered as a basic gap.

The prevalence of this infection varies according to geographical area and differences in climate, dietary habits, hygiene, and susceptibility of the host \[[@pntd.0008103.ref116]\]. The global prevalence of *T*. *gondii* infection in pregnant women is within the range of 7%-51.3% and seroprevalence in women with abnormal pregnancies is within the range of 17.5--52.3% \[[@pntd.0008103.ref093], [@pntd.0008103.ref097]\]. The overall prevalence of *T*. *gondii* varies from country to country. Moreover, in some countries it has declined dramatically over the years. For example, in France, the prevalence of *T*. *gondii* infection in pregnant women in the 1960s was 84%, in 1995, it was 54% and in 2003, it was 44%. Since France operates a congenital toxoplasmosis surveillance system; so, this system appears to be an essential tool for evaluating the efficacy of new screening strategies \[[@pntd.0008103.ref117]\].

Moreover, this study assessed the relationship between seroprevalence of anti- *T*. *gondii* antibodies and abortion. The results revealed that the ORs of prevalence of anti-*T*. *gondii* IgG antibodies in women who had spontaneous abortion were 1.65 (95% CI: 1.31--2.09) in cross-sectional and 2.26 (95% CI: 1.56--3.28) in case-control studies, compared to control group. In all of these analyses, heterogeneity was significant (I^2^ \> 50%). Variation in these studies in terms of inclusion and exclusion criteria, the diverse populations, the difference in the methods of selection of the target populations, the age of the participants in the studies, the type of study (cross-sectional or case-control studies) may contribute to heterogeneity among studies. Therefore, a meta-regression test was performed to investigate the impact of the type of study on heterogeneity. The results suggested that the type of study had a significant effect on the assessment of the relationship between anti-*T*. *gondii* IgG antibody and abortion. However, this effect was not significant for anti-*T*. *gondii* IgM antibody. Based on results of the Egger's test, there is no significant publication bias in cross-sectional studies. However, the results of Eggert's test were statistically significant in case-control studies. These findings are likely to be related to the variability of the results of preliminary studies entered the meta-analysis. It is worthy to note that usually language-bias can be a possible reason for publication bias since only English-language articles were used in this study. As the results of the \"trim and fill\" method showed that the publication bias did not have a significant effect on the study results; so, the results presented in this paper seem to be valid and it is not necessary to use other languages. Furthermore, English abstracts of articles with non- English languages, due to the lack of sufficient information for analysis, were not included in our study.

Out of 72 studies, 43 were conducted in Asia, 12 in Africa, 9 in America and 8 in Europe and none in Australia and many European and American countries have no published articles in this field. There are several risk factors for the prevalence of *T*. *gondii* in women who had spontaneous abortion, such as ethnicity, socioeconomic status, history of contact with cats, raw meat consumption, strain's virulence of *T*. *gondii*, immunological competence of the mother, smoking, and alcohol abuse. However, these risk factors were not specifically investigated in most studies and it was not possible to perform meta-analysis these risk factors.

It is important to determine the timing of abortion in relation to the measurement of seroprevalence of anti- *T*. *gondii* antibodies; because, occurrence of infection in the first trimester, when hormone levels are low and there is little helper T cell type 2 (Th2) bias, reduces the chance of transmission to the fetus but increases the likelihood of miscarriage. In contrast, the occurrence of infection in the third trimester, when there is a strong Th2 bias, makes abortion unlikely, but increases congenital transmission. The helper T cell type 1 responses caused by *T*. *gondii* infection in early pregnancy may induce miscarriage. In contrast, the strong Th2 bias and decreased natural killer cells, macrophages and CD8+ T cells function occur in the late stages of pregnancy that may contribute to parasite survival and increase the chance of congenital transmission \[[@pntd.0008103.ref118]\]. However, due to the lack of evaluation of this risk factor in most studies assessing the relationship between abortion and the seroprevalence of anti- *T*. *gondii* antibodies, or incomplete data in some studies, the timing of abortion was not analyzed and this is considered as a major gap. On the other hand, in cross-sectional studies, it is not known when the abortion or the seroconversion happened.

Results of IgG calculated in this study (43% and 33%) do not provide sufficient data for the evaluation of CT. This can be due to the fact that IgG appears approximately 2 weeks after IgM, reaches peak levels within 6--8 weeks, and starts to slowly decrease to lower levels after 1 year until the end of infected subject's life due to the persistence of latent cysts in immune-privileged organs \[[@pntd.0008103.ref018], [@pntd.0008103.ref119], [@pntd.0008103.ref120]\].

In the current study, the overall prevalence of anti- *T*. *gondii* IgM antibodies in women who had abortion in present pregnancy or a history of abortion was estimated at 1% (95% CI: 1%-2%) and 3% (95% CI: 3%-4%), respectively. IgM antibody is an indicator of recent infection and detection of specific IgM antibody can assist in the determination of acute infection. It is usually detectable 1 week after infection and declines more rapidly, compared to IgG antibody. Level of IgM antibody increases to reach peak levels after 1--3 months. There is a slow decline in antibody levels over the next 9 months until negativation \[[@pntd.0008103.ref121], [@pntd.0008103.ref122]\]. It was revealed that IgM antibodies can be detected for 12 years following the acute phase of infection \[[@pntd.0008103.ref121]\]. On the other hand, autoimmune antibodies, such as rheumatoid factor and antinuclear antibodies, non-specific in vitro binding and acute viral infection, can cause false-positive IgM results up to 60% and results of commercial kits used in reference laboratories. This can be viewed as the limitation of this method since it cannot be determined whether the patient has contracted this infection a few months ago or is in the acute phase of the disease which can put the fetus at risk \[[@pntd.0008103.ref123], [@pntd.0008103.ref124]\].

Positive IgM test results should be confirmed in reference laboratories using specific tests, such as IgG avidity, or by evaluation of IgA and IgE antibodies \[[@pntd.0008103.ref125]\]. When the IgM serologic reaction is positive in an asymptomatic patient, the IgG avidity test is an auxiliary test to distinguish between acute and chronic infection. Avidity antibodies are low in pregnant women who were infected at least 3--5 months earlier. Low-avidity may persist for 1 year. In these cases, the interpretation of the results needs more precision \[[@pntd.0008103.ref125], [@pntd.0008103.ref126]\].

It is better to study IgA antibody in pregnant women to continue the evaluation of the acute form of *T*.*gondii* infection. IgA production is similar to that of IgM and it appears during the first week, whereas IgA antibody peak occurs later than IgM and persist more than 3 or 4 months following primary infection; therefore, they disappear earlier than IgM \[[@pntd.0008103.ref127]\]. IgA may persist for more than a year \[[@pntd.0008103.ref018], [@pntd.0008103.ref120], [@pntd.0008103.ref127]\]. Therefore, it is not also sufficient in the detection of acute infection in adults \[[@pntd.0008103.ref128]\].

On the other hand, specific IgE antibodies are produced rapidly and remain detectable less than 4 months after infection by ELISA in sera of adults with acute infection, neonates infected with congenital infection, and children with chorioretinitis \[[@pntd.0008103.ref129]\]. IgE antibody may be helpful in the diagnosis of lymphadenopathies, and the persistence of IgE can be an indicator of active toxoplasmosis \[[@pntd.0008103.ref130]\]. Although IgE seropositivity occurs for a briefer period than IgM or IgA antibodies and it is useful for the diagnosis of the acute form \[[@pntd.0008103.ref131], [@pntd.0008103.ref132]\], it does not have enough sensitivity \[[@pntd.0008103.ref130]\].

In pregnant women, confirmation of active toxoplasmosis in reference laboratories can be achieved by the inoculation of body fluids or tissues in mouse or cell culture \[[@pntd.0008103.ref018]\]. Mouse inoculation is absolutely sensitive; however, it requires the use of live animals, housing, euthanasia, autopsy and antibody testing. In addition, it takes a maximum of 6 weeks to obtain a diagnosis and is not widely available method for modem clinical laboratories \[[@pntd.0008103.ref133], [@pntd.0008103.ref134]\]. Cell culture is a practical method for the detection of *T*. *gondii* than mouse inoculation; however, it is relatively slow and may not be sensitive \[[@pntd.0008103.ref135]\].

Unfortunately, in spite of the importance of cell culture and mouse inoculation for the detection of *T*. *gondii*, most researchers have not used these techniques in their researches. Moreover, polymerase chain reaction can be performed on amniotic fluid to detect *T*. *gondii*-specific DNA after 18 weeks of pregnancy \[[@pntd.0008103.ref136]\].

Limitations {#sec021}
-----------

The limitations of the present study include: 1) lack of large cohort of women with *T*. *gondii* infection, as compared to controls for the investigation of the association between abortion and *T*. *gondii* infection (because cross-sectional and case-control studies due to their nature, do not provide the possibility to explore the causal relationship), 2) the diversity of the diagnostic methods with different sensitivity and specificity, 3) The use of English articles due to lack of fluency in other languages.

Conclusion {#sec022}
----------

Since the pooled ORs for anti-*T*. *gondii* IgG and IgM antibodies in different studies among women who had spontaneous abortion were higher than controls, it shows a possible relationship between *T*. *gondii* and spontaneous abortion. Hence, emphasize on health education especially on the *Toxoplasma* transmission routes in the childhood, and performance of screening program using regular serologic tests during pregnancy could help physicians in the diagnosis, prevention, and treatment of toxoplasmosis and reduction of the economic burden of the disease on society.
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Click here for additional data file.

###### Funnel plot to detect publication bias in cross-sectional studies showing IgG seropositivity rates of *T*. *gondii*.

(TIF)

###### 

Click here for additional data file.

###### Funnel plot to detect publication bias in case-control studies showing IgG seropositivity rates of *T*. *gondii*.

(TIF)

###### 

Click here for additional data file.

###### Funnel plot to detect publication bias in case-control studies showing IgG seropositivity rates of *T*. *gondii* after estimating censored studies.

(TIF)

###### 

Click here for additional data file.

###### Sensitivity analysis for assessing the effect of each primary study on the total estimates in cross-sectional studies showing IgG seropositivity rates of *T*. *gondii*.

(TIF)

###### 

Click here for additional data file.

###### Sensitivity analysis for assessing the effect of each primary study on the total estimates in case-control studies showing IgG seropositivity rates of *T*. *gondii*.

(TIF)

###### 

Click here for additional data file.

###### Funnel plot to detect publication bias in cross-sectional studies showing IgM seropositivity rates of *T*. *gondii*.

(TIF)

###### 

Click here for additional data file.

###### Funnel plot to detect publication bias in cross-sectional studies showing IgM seropositivity rates of *T*. *gondii* after estimating censored studies.

(TIF)

###### 

Click here for additional data file.

###### Funnel plot to detect publication bias in case-control studies showing IgM seropositivity rates of *T*. *gondii*.

(TIF)

###### 

Click here for additional data file.

###### Funnel plot to detect publication bias in case-control studies showing IgM seropositivity rates of *T*. *gondii* after estimating censored studies.

(TIF)

###### 

Click here for additional data file.

###### Sensitivity analysis for assessing the effect of each primary study on the total estimates in cross-sectional studies showing IgM seropositivity rates of *T*. *gondii*.

(TIF)

###### 

Click here for additional data file.

###### Sensitivity analysis for assessing the effect of each primary study on the total estimates in case-control studies showing IgM seropositivity rates of *T*. *gondii*.

(TIF)

###### 

Click here for additional data file.
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